oral lung penetrant RSV fusion inhibitor

Ph. II candidate (50 mg BID) for RSV infect.

opt. from literature starting point

J. Med. Chem., Mar. 17, 2021

Reviral Ltd, Hertfordshire, UK

Structure of Sisunatovir - syncytial virus (RSV) fusion inhibitor

The Reviral respiratory syncytial virus (RSV) fusion inhibitor (sisunatovir) is an oral Ph. II clinical candidate that demonstrated reduction in viral load and total symptom score in RSV-infected patients…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: